United States Age-Related Macular Degeneration Market 2035 Outlook | Key Growth Drivers, Breakthrough Treatments, Competitive Landscape & High-Value Investment Opportunities

Market Size and Growth 2026

The Age-Related Macular Degeneration Market is estimated to reach USD 16.40 Billion in 2025 and is projected to grow to USD 30.03 Billion by 2035, registering steady growth at a CAGR of 6.3% during the forecast period from 2026 to 2035.

Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/age-related-macular-degeneration-market?sb

DataM Intelligence has released a new research report titled Age-Related Macular Degeneration Market Size 2026 The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the global Age-Related Macular Degeneration market.

Key Developments 2025-2026:

United States: Recent Industry Developments

✅ In March 2026, Regeneron Pharmaceuticals advanced its clinical pipeline for next-generation anti-VEGF therapies targeting wet AMD, focusing on longer-acting treatment intervals and improved retinal outcomes. The development aims to reduce injection burden for patients. It strengthens Regeneron's leadership in retinal disease therapeutics.

✅ In February 2026, Apellis Pharmaceuticals expanded real-world adoption programs for its complement inhibitor therapy used in geographic atrophy linked to dry AMD. The initiative focuses on improving early intervention and patient access. It reinforces Apellis' role in complement-targeted eye treatments.

✅ In January 2026, AbbVie progressed late-stage studies for novel ophthalmology biologics aimed at slowing AMD progression through inflammation pathway modulation. The research targets long-term vision preservation. It strengthens AbbVie's expansion into retinal disease innovation.

✅ In January 2026, Bausch + Lomb launched enhanced ophthalmic diagnostic solutions supporting earlier detection of AMD in high-risk populations. The tools integrate advanced imaging and AI-assisted screening. It improves early-stage intervention capabilities in eye care.

Ready to scale in the Age-Related Macular Degeneration Market? Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/age-related-macular-degeneration-market?sb

Japan: Recent Industry Developments

✅ In March 2026, Santen Pharmaceutical advanced its ophthalmology R&D programs focusing on next-generation therapies for dry AMD and retinal degeneration. The research emphasizes neuroprotection and disease slowing mechanisms. It strengthens Japan's leadership in eye health innovation.

✅ In February 2026, Nippon Boehringer Ingelheim expanded collaborations in retinal disease research targeting inflammatory pathways involved in AMD progression. The initiative focuses on combination therapies for improved outcomes. It enhances Japan's ophthalmic innovation ecosystem.

✅ In January 2026, Otsuka Pharmaceutical increased investment in ophthalmology-focused biologics research for degenerative retinal conditions including AMD. The focus is on long-term vision preservation and disease modification. It supports Japan's growing retinal therapy pipeline.

✅ In January 2026, Kowa Company advanced development of small-molecule therapies aimed at slowing retinal damage in AMD patients. The program emphasizes early-stage intervention strategies. It strengthens Japan's presence in retinal drug innovation.

List of Key Players 2026:

=> F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Novartis AG, Apellis Pharmaceuticals, Inc., Astellas Pharma Inc., Biocon, Samsung Bioepis, Bausch + Lomb, Alcon Inc., and Nature Made, among others.

Request Strategic Market Customization: https://datamintelligence.com/customize/age-related-macular-degeneration-market?sb

Growth Forecast Projection 2026:

The Global Age-Related Macular Degeneration Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2035. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

How Our Market Research Process Works:

The global Age-Related Macular Degeneration Market research report is developed using a comprehensive combination of primary and secondary data sources. The study evaluates a wide range of industry-influencing factors, including government regulations, evolving market dynamics, competitive intensity, and historical performance trends. It also analyzes technological advancements, emerging innovations, and developments across related industries. In addition, the report assesses market volatility, growth opportunities, potential barriers, and key challenges that could impact the future expansion of the Age-Related Macular Degeneration ecosystem.

Recent Mergers & Acquisitions (M & A) 2025-2026:

In April 2026
✅ F. Hoffmann-La Roche expanded its ophthalmology portfolio through continued investment in retinal disease therapies, strengthening its AMD pipeline centered on anti-VEGF and complement inhibition programs.

✅ Regeneron Pharmaceuticals advanced strategic collaborations for next-generation wet AMD biologics, reinforcing long-term commercialization partnerships in retinal disease treatment.

In March 2026
✅ Novartis continued portfolio optimization in ophthalmology by strengthening licensing and development agreements focused on gene therapies and sustained-release AMD treatments.

✅ Mid-cap biotech consolidation activity increased in the retinal disease space, with multiple small acquisition talks focused on complement pathway inhibitors and regenerative eye therapies, reflecting rising interest in dry AMD innovation pipelines.

In February 2026
✅ Apellis Pharmaceuticals continued strategic expansion of its complement C3 inhibitor franchise, driving partnership discussions to extend reach into broader geographic markets for geographic atrophy (dry AMD).

✅ Alcon strengthened its retinal care ecosystem through targeted investments and selective acquisition scouting in diagnostic and surgical ophthalmology technologies linked to AMD management.

Unlock Full 360° Strategic Report: https://www.datamintelligence.com/buy-now-page?report=age-related-macular-degeneration-market?sb

Major Focused Key Segmentations 2026:

➥ By Type: Dry AMD, Wet AMD

➥ By Treatment: Anti-VEGF Drugs, AREDS2 Supplements, Photodynamic Therapy, Others

➥ By Patient Type: Male, Female

➥ By Region: North America, Latin America, Europe, Asia Pacific, Middle East & Africa - Share, Size, Outlook, and Opportunity Analysis (2026-2035)

Regional Growth Analysis for Market:

⇥ North America: Leads the Age-Related Macular Degeneration market with strong R&D investments, advanced material innovation, and growing adoption across electronics, energy storage, and aerospace sectors.

⇥ Asia-Pacific (including Japan): Dominates global demand, driven by large-scale production, expanding applications in electronics, batteries, and industrial manufacturing across China, Japan, and India.

⇥ Europe: Significant growth supported by government-funded research initiatives, sustainability focus, and increasing use in automotive and renewable energy applications.

⇥ Middle East & Africa: Emerging market fueled by rising interest in advanced materials, infrastructure development, and early-stage adoption in energy and construction sectors.

We Provide Benefits of the Report:

Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.

Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.

Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.

Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.

Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.

Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.

Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.

Chapter 9: Maps the industry's supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.

Chapter 10: Wraps up with a concise summary of the report's key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.

FAQ

Q1: What is the current size of the Age-Related Macular Degeneration Market?

A: The Age-Related Macular Degeneration Market was valued at USD 16.40 Billion in 2025 and is forecasted to hit USD 30.03 Billion by 2035

Q2: How rapidly will the Market expanding?

A: The Age-Related Macular Degeneration market is projected to grow at a CAGR of 6.3% between 2026 and 2035.

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.